Department of Internal Medicine & AIDS Research Institute, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul 120-752, Korea.
Immunotherapy. 2011 Feb;3(2):247-67. doi: 10.2217/imt.10.91.
While the development of combined active antiretroviral therapy (cART) has dramatically improved life expectancies and quality of life in HIV-infected individuals, long-term clinical problems, such as metabolic complications, remain important constraints of life-long cART. Complete immune restoration using only cART is normally unattainable even in cases of sufficient plasma viral suppression. The need for immunologic adjuncts that complement cART remains, because while cART alone may result in the complete recovery of peripheral net CD4+ T lymphocytes, it may not affect the reservoir of HIV-infected cells. Here, we review current immunotherapies for HIV infection, with a particular emphasis on recent advances in cytokine therapies, therapeutic immunization, monoclonal antibodies, immune-modulating drugs, nanotechnology-based approaches and radioimmunotherapy.
虽然联合抗逆转录病毒疗法 (cART) 的发展极大地提高了 HIV 感染者的预期寿命和生活质量，但长期的临床问题，如代谢并发症，仍然是长期 cART 的重要限制。即使在充分抑制血浆病毒的情况下，仅使用 cART 也通常无法实现完全免疫恢复。因此，仍然需要免疫辅助治疗来补充 cART，因为虽然 cART 单独使用可能导致外周净 CD4+T 淋巴细胞完全恢复，但它可能不会影响 HIV 感染细胞的储存库。在这里，我们回顾了 HIV 感染的当前免疫疗法，特别强调了细胞因子疗法、治疗性免疫接种、单克隆抗体、免疫调节药物、基于纳米技术的方法和放射免疫疗法的最新进展。
